[Current Controversies in Risk-adapted Therapy in Differentiated Thyroid Cancer: Is Less (therapy) Really More?]

Overview

Journal Wien Med Wochenschr

Specialty General Medicine

Date 2019 Dec 5

PMID 31797245

Authors

Amir Kurtaran

Brigitta Schmoll-Hauer

Christina Tugendsam

Affiliations

Soon will be listed here.

Abstract

In recent years, there has been worldwide a significant (relative) increase in "small" thyroid cancer (pT1 = tumor size of ≤10 mm), which has now reached a plateau. This fact and the absence of prospective and randomized clinical trials are increasingly leading to a discussion of the so-called risk-adapted management of differentiated thyroid cancer. The available studies are partly incomplete, retrospective and difficult to compare. In addition, factors such as different iodine supply, cost-benefit considerations and regional differences in quality of surgical procedures influence the implementation of therapy concepts. Therefore, the therapy of the differentiated thyroid cancer is currently the subject of intensive discussion, especially in "low risk" situations. There is a worldwide trend to classify the risk of differentiated thyroid cancer in general lower than in the past and thus also to reduce the extent of the traditionally recommended therapy. The discussion is increasingly moving from the "one size fits all" towards personalized and thus risk-adapted therapy of the differentiated thyroid cancer.The main goal of this "paradigm shift" is to avoid an "overtreatment" which may be associated with permanent complications due to "unnecessary" surgical procedures and any negative effects of radioiodine ablation.This overview attempts to answer the following questions: When is a risk-adapted therapy for differentiated thyroid cancer justified? What are the consequences in differentiated thyroid cancer if no radioiodine therapy is performed?

References

Hirsch D, Shohat T, Gorshtein A, Robenshtok E, Shimon I, Benbassat C . Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer. Thyroid. 2016; 26(8):1110-6. DOI: 10.1089/thy.2016.0037. View

Pryma D . Controversies on the Use of Radioiodine in Thyroid Cancer: We Need More and Better Data. J Nucl Med. 2018; 59(8):1184-1186. DOI: 10.2967/jnumed.118.214197. View

Ardito G, Revelli L, Giustozzi E, Salvatori M, Fadda G, Ardito F . Aggressive papillary thyroid microcarcinoma: prognostic factors and therapeutic strategy. Clin Nucl Med. 2012; 38(1):25-8. DOI: 10.1097/RLU.0b013e318279bc65. View

SAENGER E, THOMA G, Tompkins E . Incidence of leukemia following treatment of hyperthyroidism. Preliminary report of the Cooperative Thyrotoxicosis Therapy Follow-Up Study. JAMA. 1968; 205(12):855-62. View

Rubino C, De Vathaire F, Dottorini M, Hall P, Schvartz C, Couette J . Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003; 89(9):1638-44. PMC: 2394426. DOI: 10.1038/sj.bjc.6601319. View

Park E, Chung J, Lim I, Park D, Lee D, Lee M . Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. Eur J Nucl Med Mol Imaging. 2008; 36(2):172-9. DOI: 10.1007/s00259-008-0912-0. View

Campenni A, Giovanella L, Pignata S, Vento A, Alibrandi A, Sturiale L . Undetectable or low (<1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients. Oncotarget. 2018; 9(25):17491-17500. PMC: 5915131. DOI: 10.18632/oncotarget.24766. View

Mitchell A, Gandhi A, Scott-Coombes D, Perros P . Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016; 130(S2):S150-S160. PMC: 4873931. DOI: 10.1017/S0022215116000578. View

Mazzaferri E . Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid. 1997; 7(2):265-71. DOI: 10.1089/thy.1997.7.265. View

10.

Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B . Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012; 366(18):1663-73. DOI: 10.1056/NEJMoa1108586. View

11.

Brown R . Standard and emerging therapeutic approaches for thyroid malignancies. Semin Oncol. 2008; 35(3):298-308. DOI: 10.1053/j.seminoncol.2008.03.011. View

12.

Machens A, Holzhausen H, Dralle H . The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer. 2005; 103(11):2269-73. DOI: 10.1002/cncr.21055. View

13.

Teng C, Hu Y, Chen S, Yeh C, Chiang H, Chen T . Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study. J Natl Cancer Inst. 2015; 108(2). DOI: 10.1093/jnci/djv314. View

14.

Jo P, Kesruek H, Nietert M, Sahlmann C, Gaedcke J, Ghadimi M . [Incidence and Predictive Factors for Bilaterality in Patients with Papillary Thyroid Carcinoma]. Zentralbl Chir. 2018; 143(4):361-366. DOI: 10.1055/a-0651-0878. View

15.

Li N, Du X, Reitzel L, Xu L, Sturgis E . Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008. Thyroid. 2012; 23(1):103-10. PMC: 3539256. DOI: 10.1089/thy.2012.0392. View

16.

Gschwandtner E, Klatte T, Swietek N, Bures C, Kober F, Ott J . Increase of papillary thyroid microcarcinoma and a plea for restrictive treatment: A retrospective study of 1,391 prospective documented patients. Surgery. 2015; 159(2):503-11. DOI: 10.1016/j.surg.2015.06.015. View

17.

Qu N, Zhang L, Ji Q, Zhu Y, Wang Z, Shen Q . Number of tumor foci predicts prognosis in papillary thyroid cancer. BMC Cancer. 2014; 14:914. PMC: 4289292. DOI: 10.1186/1471-2407-14-914. View

18.

Brendel A, Lambert B, Guyot M, Jeandot R, Dubourg H, Roger P . Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma. Eur J Nucl Med. 1990; 16(1):35-8. DOI: 10.1007/BF01566010. View

19.

Dietlein M, Eschner W, Grunwald F, Lassmann M, Verburg F, Luster M . [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Version 4]. Nuklearmedizin. 2016; 55(3):77-89. View

20.

Radivoyevitch T, Sachs R, Gale R, Molenaar R, Brenner D, Hill B . Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation. Leukemia. 2015; 30(2):285-94. DOI: 10.1038/leu.2015.258. View